๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Myeloproliferative Disease

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants NCT06787144Phase 14 sites๐Ÿ“ Akita๐Ÿ“ Sapporo๐Ÿ“ Suita-shi Enliven Therapeutics ยท Tests: ELVN-001 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate Pacritinib in CMML NCT06159491Phase 1, Phase 21 site๐Ÿ“ New York Douglas Tremblay ยท Tests: Pacritinib, Azacitidine A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676Phase 111 sites๐Ÿ“ Duarte๐Ÿ“ Palo Alto๐Ÿ“ Tampa Crossbow Therapeutics, Inc. ยท Tests: CBX-250 International Chronic Myeloid Leukemia Pediatric Study NCT01281735n/a20 sites๐Ÿ“ North Adelaide๐Ÿ“ Vienna๐Ÿ“ Minsk Poitiers University Hospital A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms NCT06034002Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Palo Alto๐Ÿ“ Miami Incyte Corporation ยท Tests: INCA033989, Ruxolitinib TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients NCT06088888Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Seattle Shenzhen TargetRx Co., Ltd. ยท Tests: TGRX-678 Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood NCT00662090n/a1 site๐Ÿ“ Freiburg im Breisgau University Hospital Freiburg Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations NCT07143669n/a26 sites๐Ÿ“ Birmingham๐Ÿ“ Birmingham๐Ÿ“ Scottsdale Blueprint Medicines Corporation ยท Tests: Screening Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen NCT06532084Phase 21 site๐Ÿ“ Saint Petersburg St. Petersburg State Pavlov Medical University ยท Tests: Sorafenib CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04493164Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance NCT06740916Phase 31 site๐Ÿ“ Bangkok Noi Siriraj Hospital ยท Tests: 81-mg aspirin once daily, 81-mg aspirin twice daily High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly NCT06345495Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam, Eltrombopag, Busulfan A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts NCT05365035Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cladribine, Cytarabine, Venetoclax, Azacitidine Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation NCT06138587Phase 12 sites๐Ÿ“ Boston๐Ÿ“ Boston Dana-Farber Cancer Institute ยท Tests: Cytokine Induced Memory-like Natural Killer Cells, Interleukin-2 Impact of Targeted Therapy on Cancer-Related Cognitive Impairment NCT07638007n/a1 site๐Ÿ“ Rochester University of Rochester NCORP Research Base Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis NCT04370301Phase 21 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia NCT07394153Phase 213 sites๐Ÿ“ Barcelona๐Ÿ“ Barcelona๐Ÿ“ Barcelona Grupo Espaรฑol de Enfermedades Mieloproliferativas Crรณnicas โ€ฆ ยท Tests: Pacritinib A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites๐Ÿ“ Birmingham๐Ÿ“ Gilbert๐Ÿ“ Phoenix Center for International Blood and Marrow Transplant Researโ€ฆ ยท Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) A Telehealth Advance Care Planning Intervention NCT05875805NA1 site๐Ÿ“ Rochester University of Rochester ยท Tests: Telehealth Serious Illness Care Program, Education Control A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms NCT07849231Phase 136 sites๐Ÿ“ Birmingham๐Ÿ“ Gilbert๐Ÿ“ Duarte Damora Therapeutics ยท Tests: DMR-001, Ruxolitinib MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms NCT07863466n/a1 site๐Ÿ“ Milan Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor NCT07238712Phase 21 site๐Ÿ“ Saint Petersburg St. Petersburg State Pavlov Medical University ยท Tests: Ruxolitinib, Abatacept (Orencia) A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy NCT07091019n/a17 sites๐Ÿ“ Birmingham๐Ÿ“ Stockton๐Ÿ“ Torrance Novartis Pharmaceuticals ยท Tests: TKIs Evaluation of the Pathobiology of CALR-mutated MPN Cells NCT06480591n/a2 sites๐Ÿ“ Charlotte๐Ÿ“ Winston-Salem Wake Forest University Health Sciences ยท Tests: Blood Draw Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms NCT05850273n/a1 site๐Ÿ“ Villejuif Institut National de la Santรฉ Et de la Recherche Mรฉdicale, โ€ฆ A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS NCT05788679Phase 21 site๐Ÿ“ Stockholm Karolinska University Hospital ยท Tests: Azacitidine, Donor lymphocytes, Tapering of immune suppression A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany NCT07549516n/a69 sites๐Ÿ“ Baden-Baden๐Ÿ“ Heidenheim๐Ÿ“ Schwรคbisch Hall Novartis Pharmaceuticals Efficacy and Safety of Generic Imatinib (Carcemiaยฎ) Compared to Glivecยฎ in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia NCT05282108n/a4 sites๐Ÿ“ Cairo๐Ÿ“ Cairo๐Ÿ“ Cairo Hikma Pharmaceuticals LLC ยท Tests: Carcemia, Glivec Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy